Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: Part II - Leukemia and myeloma

29Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND. The objective of this study was to estimate the ideal proportion of new patients with leukemia and myeloma who should receive radiotherapy at some time during the course of their illness based on the best evidence. METHODS. Available evidence of the efficacy of radiotherapy in most clinical situations for leukemia and myeloma was identified through extensive literature reviews and treatment guideline searches. Epidemiologic data concerning the distribution of types, disease stages, and other factors that influence the use of radiotherapy were identified. Decision trees were constructed to merge the evidence-based recommendations with the epidemiological data to calculate the optimal proportion of patients who should receive radiotherapy according to the best available evidence. Actual radiotherapy utilization rates also were identified. RESULTS. The proportion of patients diagnosed with myeloma in Australia who should receive radiotherapy based on the evidence was 38%. There was wide variation in the proportion of patients who actually received radiotherapy for myeloma from 24% up to 55%. The recommended proportion of patients diagnosed with myeloma in Australia who, according to the best available evidence, should receive at least a single course of radiotherapy was 38%. The proportion of patients diagnosed in Australia with leukemia who should receive radiotherapy at some point in their management, according to the best available evidence, was calculated at 4%, which corresponded with actual practice. CONCLUSIONS. Further research will be required to determine why more patients who are diagnosed with myeloma are not treated with radiotherapy. © 2004 American Cancer Society.

References Powered by Scopus

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma

2690Citations
N/AReaders
Get full text

The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial

2450Citations
N/AReaders
Get full text

Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma

1013Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines

1374Citations
N/AReaders
Get full text

Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012

415Citations
N/AReaders
Get full text

Second malignancies after multiple myeloma: From 1960s to 2010s

103Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Featherstone, C., Delaney, G., Jacob, S., & Barton, M. (2005). Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: Part II - Leukemia and myeloma. Cancer, 103(2), 393–401. https://doi.org/10.1002/cncr.20755

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

42%

Researcher 5

26%

Lecturer / Post doc 4

21%

Professor / Associate Prof. 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

84%

Nursing and Health Professions 1

5%

Social Sciences 1

5%

Engineering 1

5%

Save time finding and organizing research with Mendeley

Sign up for free